Skip to content

PTHS PTHS Accrued Manufacturing Costs

Accrued Manufacturing Costs at other companies

Theravance Biopharma logo
Theravance BiopharmaTBPH
HRO
HarrowHROW
Arcutis Biotherapeutics, Inc. logo
Arcutis Biotherapeutics, Inc.ARQT

Other financials

Income statement

See full
Revenue$10.9M
Gross profit$9.2M
Operating income-$13.1M-614%
Net income-$10.2M-420%
EPS (diluted)-$3.09+3.7%

Balance sheet

See full
Cash & equivalents$32.0M+24,250%
Total debt$29.6M
Total equity$35.1M+937%
Total assets$145.4M+15,855%

Cash flow

See full
Operating cash flow-$13.1M-1,977%
CapEx$194.0K
Free cash flow-$13.3M-2,008%

Valuation

See full
Market cap$98.22M+75.4%
Enterprise value$95.89M
P/S3.6×

Profitability

See full
Gross margin79.6%
Operating margin-157.7%
Net margin-186.2%
FCF margin-60.8%

Returns & leverage

See full
Return on equity-333.8%
Debt / equity0.8×
Current ratio2.8×+2.6×

Where this comes from

Reported directly by PTHS in its filing.

Tagged under the XBRL concept us-gaap:EmployeeRelatedLiabilitiesCurrent.

The official record: PTHS’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about PTHS's accrued manufacturing costs.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is PTHS's accrued manufacturing costs?
PTHS (PTHS) reported accrued manufacturing costs of $1.93M in Q1 2026.